This paper is only available as a PDF. To read, Please Download here.
Abstract
Diabetes mellitus is a chronic disease that affects many aspects of the lives of diagnosed
patients and their families, the health care industry, and society. The majority of
the economic literature on diabetes addresses the cost of treating diabetes but not
the outcomes of clinical interventions. The primary cost of treating diabetes is related
to short-term care to achieve euglycemia and long-term care associated with complications
of the disease. The short-term costs of achieving euglycemia can be overshadowed by
the decreased risk of long-term complications. The difficulty of providing care for
a chronic disease such as diabetes arises from the high short-term costs of clinical
interventions, the positive benefits of which may not be realized for many years.
The results of the Diabetes Control and Complications Trial show a correlation between
the intensive treatment of diabetes and a decreased risk of the development of long-term
complications. Whether intensive treatment is practical, effective, and cost-effective
in a real-world setting is a topic for further study. In the meantime, health care
providers with a good knowledge of the clinical and economic elements of available
therapeutic options can develop individualized care regimens for their patients with
diabetes that are high quality and cost-effective
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Diabetes 1996 Vital Statistics. American Diabetes Association, Rockville, MD1996
- The economic costs of non-insulin-dependent diabetes mellitus.JAMA. 1989; 262: 2708-2713
- The cost of diabetes and its complications.Soc Sci Med. 1992; 35: 1303-1310
- Economic analysis of diabetes.J Diabetes Complications. 1996; 10: 149-150
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.NEJM. 1993; 329: 977-986
- Harris MI Cowie CC Stern MP 2nd ed. Diabetes in America. National Institutes of Health, Washington, DC1995 (NIH publication 95-1468)
- Costs of temporary and permanent disability induced by diabetes.Diabetes Care. 1991; 14: 593-596
- Definitions and conceptual issues.in: Spilker B Quality of Life Assessments in Clinical Trials. Raven Press, New York, NY1990: 11-25
- Beneficial effects of improved glycemic control with glipizide: GITS on quality of life and symptom distress in NIDDM.56th Annual Meeting and Scientific Sessions of the American Diabetes Association. 8111996; (San Francisco, Calif. Abstract)
- White paper on healthcare reform.Diabetes Educ. 1994; 20: 479-482
- The integrated approach to diabetes mellitus: The impact of clinical information systems, consumerism, and managed care.Diabetes Spectrum. 1996; 9: 158-163
- The World Almanac® and Book of Facts 1994. K-III Reference Corporation, Mahwah, NJ1993
- Health care expenditures for people with diabetes mellitus, 1992.J Clin Endocrinol Metab. 1994; 78: 809A-809F
- Resource utilization and costs of care in the Diabetes Control and Complications Trial.Diabetes Care. 1995; 18: 1468-1478
- ACPE continuing education series: The value of pharmaceutical care patients with diabetes. 26. Eli Lilly and Company, Indianapolis, Ind1995 (ACPE Program #680 302-95-081)
- Utilization trends and risk factors for hospitalization in diabetes mellitus.Mayo Clin Proc. 1990; 65: 1171-1184
- Hospital use among diabetic patients and the general population.Diabetes Care. 1994; 17: 1320-1329
- The cost of hospitalization for the late complications of diabetes in the United States.Diabetic Med. 1991; 8 (Suppl): S23-S29
- Diabetes and managed care. The reality.Pract Diabetology. 1994; : 2-6
- Use of health maintenance organization data bases to study pharmacy resource usage in diabetes mellitus.Diabetes Care. 1992; 15: 870-876
- Implications of the Diabetes Control and Complications Trial.Diabetes Spectrum. 1993; 6: 225-227
- Introduction: Risks and benefits of intensive management in non—insulin-dependent diabetes mellitus. The fifth Regenstrief conference.Ann Intern Med. 1996; 124 (Pt 2): 81-85
- The applicability and implications of the DCCT to NIDDM.Diabetes Rev. 1994; 2: 413-427
- Barriers to the translation of the Diabetes Control and Complications Trial.Diabetes Rev. 1994; 2: 371-383
- Type II diabetes mellitus: Disease state management.Retail Pharmacy News. 1995; (September): 11-16
- A Core Curriculum for Diabetes Education. 1996; (Addendum to second edition, Chicago, Ill: American Association of Diabetes Educators)
- Reverse iontophoresis: Noninvasive glucose monitoring in vivo in humans.Pharm Res. 1995; 12: 1869-1873
- Measurement of glucose in diabetic subjects using noninvasive transdermal extraction.Nat Med. 1995; 1: 1198-1201
- Effects of troglitazone. A new hyperglycemic agent in patients with NIDDM poorly controlled by diet therapy.Diabetes Care. 1996; 19: 151-156
- New therapeutic agents for the treatment of NIDDM.Exp Clin Endocrinol Diabetes. 1996; 104: 93-101
- Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.Am J Hypertens. 1995; 8: 316-320
- Efficacy and safety of tolrestat in the treatment of patients with peripheral sensorimotor diabetic neuropathy: An open-label, uncontrolled, pilot study.Curr Ther Res. 1996; 57: 215-229
- Tolrestat in the primary prevention of diabetic neuropathy.Diabetes Care. 1995; 18: 536-541
- Perspectives in diabetes: The aldose reductase controversy.Diabetes. 1994; 43: 169-172
- Aldose reductase inhibitors: An update.Ann Pharmacother. 1993; 27: 751-754
Article info
Identification
Copyright
© 1997 Published by Elsevier Inc.
